Post-marketing surveillance to gather information regarding the tolerance and efficacy of Spiriva® 18 micrograms in patients with COPD under conditions of daily practice.
Study Type
OBSERVATIONAL
Enrollment
4,700
Tiotropium bromide 18 micrograms
Change from baseline in breathlessness when walking/climbing stairs
Time frame: Baseline, after 4 weeks
Change from baseline in breathlessness on physical exercise
Time frame: Baseline, after 4 weeks
Change from baseline in breathlessness during everyday activities
Time frame: Baseline, after 4 weeks
Change from baseline in breathlessness during housework
Time frame: Baseline, after 4 weeks
Change from baseline in overall severity of the clinical picture
Time frame: Baseline, after 4 weeks
Occurrence of Adverse Events
Time frame: 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.